Apart from process equipment and turnkey facilities, we offer process development services. These are to support clients' specific needs and requirements for cell culture process development and optimization.
Our capabilities includes developmental services from Upstream to downstream bioprocessing, analytical testing via process analytical technology (PAT) as well as chemistry, manufacturing, and controls (CMC) regulatory approval of your products.
With our in-depth understanding of the Asian market, we adopt a customisable approach in delivering sustainable risk-adjusted returns to our clients.
We are the industry’s leaders and expert in Upstream Processing (USP) development using our Tide Motion® bioreactors.
We support an integrated approach to service delivery to increase viral expression titer, multiplicity of infection (MOI), and increase cell viability at high-density cultures.
CelCradle X®
Semi-Automated
Harvester
(CCX-SAH)
TideXcell®
Harvesting System
(TXLHS)
TideXcell™
3,500 up to 5,000 L
Tide 2mm/s: 3,000 - 5,000 L (st. st. tanks)
Tide 6mm/s: 55,000 L
Large st. st. tank,scale for secreted virus production, viral vectors, cellular agriculture (optional edible scaffolds), or biosimilars/biobetters
TideXcell™
300 L
TideXcell™
100 L
TideXcell™
20 L
TideXcell™
2 L
CelCradle X®;
with Semi-automated Harvester Esco standalone bioreactor. Single Bottle, Optional Docking to Isolator.
CelCradle® + CelShaker™
An ESCO standalone bioreactor using single bottle, equipped with semi-automated harvester.
optional docking to Isolator available as per request.
CelXrocker™
A laboratory Tide Motion shaker for process optimization of adherent cell culture.
~Seed from 20,000-60,000 cells/carrier
CHO library suits the expression of recombinant proteins, monoclonal antibodies, and biosimilars implemented with our proprietary bioreactors in a small footprint
Bioprocess optimization using Design-of-Experiments methodology in optimizing cultivations and unit operations
Animal component free media adapted to USP processes and lowering impurities
Robust proprietary technology platform that is scalable up to 5,000 liters capacity
Customizable and reprogrammable fed-batch, continuous, and perfusion mode(s) in hypoxia and/or anaerobic conditions
We integrate a Quality by Design (QbD) approach (based on ICH Q8-11), which is a global regulatory initiative with the goal of enhancing pharmaceutical development through the proactive design of pharmaceutical manufacturing process and controls to consistently deliver the intended performance of the product.
We offer a development platform in a modular approach, in which the customer can either choose a specific module or request for the entire process development package from bench to scale.
Optimization of the developed process aiming at:
Optimization of the developed process aiming at:
On completion of the development activity, our bioengineers will propose the most feasible downstream processing systems tailored for your project requirement.
Note:
Applications where the harvested cells are the final product, tangential flow filtration (TFF) combined with a clarification step will consolidate the final downstream platform.
Esco offers complete documentation of the development services including: